the Ethics Blog
Consent based on trust rather than information?
Source: Pär Segerdahl 2017-03-21
More biobank ethics and law
Source: Josepine Fernow 2017-03-13
Stem cells: unique biobank material?
Source: Pär Segerdahl 2017-03-07
Stem cell therapy remains a form of treatment
Source: Pär Segerdahl 2017-02-27
Commercialization, but not at any price
Source: Pär Segerdahl 2017-02-14
Not just facts, ideas are also needed
Source: Pär Segerdahl 2017-02-08
How should we think about it?
Source: Pär Segerdahl 2017-01-24
The pharmaceutical industry and altruism
Source: Pär Segerdahl 2017-01-16
Ethics and law of stem cell treatment of diabetes
Source: Pär Segerdahl 2016-12-21
Research data, health cyberspace and direct-to-consumer genetic testing
Source: Josepine Fernow 2016-12-14
News from CRB
- James Giordano joins the CRB neuroethics team 2017-03-14
- Stem cells: a new type of biobank material? 2017-03-06
- A new Swedish legal framework for handling alleged misconduct 2017-03-06
- B3Africa: first 18 months 2017-03-03
- New Swedish legal officer in the BBMRI-ERIC ELSI helpdesk 2017-03-03
- We need to discuss the ethics of technology 2017-03-01
- Ulrik Kihlbom Associate Professor of Medical Ethics 2017-03-01
- New study on children’s rights in biomedicine 2017-01-24
- New research ethics training for supervisors 2016-12-20
- Swedish research data inquiry on exceptions 2016-12-13
- New research on cyber governance of health data 2016-12-09
- Legal aspects of direct-to-consumer genetic testing 2016-12-07
- Swedish radio about genetics, ethics and law 2016-11-10
- Funding for ethical and legal aspects of stem cell research 2016-11-02
- Giving patients a voice in drug development 2016-10-18
- Parent’s views on genetic screening before pregnancy 2016-10-17
- We need to discuss equity in health care 2016-10-04
- Managing data protection in practice – Swedish perspectives 2016-09-26
- Public-private research partnerships: Workshop 2016-09-23
- Informed consent guidelines listed among IRDiRC Recognized Resources 2016-09-22
Stem cell treatment of type 1 diabetes
We provide ethical and legal analysis and guidance on development of products for treating type 1 diabetes, using cells derived from human embryonic stem cells.
What's on at CRB
- Critical considerations about the use of poverty measures in the study of cognitive development
- Primary care physicians’ attitudes regarding CVD risk communication - a best worst scaling experiment
- Sound-centered memories: the ethical consequences of listening to violent acts. An interdisciplinary approach
- Attitudes to data linkage in the UK and Sweden
- Predictive coding and content of consciousness
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Your DNA Your SAy
>> Tell us what you think
This is a film-survey experience on DNA and medical data sharing.
Meet a PhD student
>> Amal Matar
Find out what Amal Matar has to say about cultural sensitivity and reproductive ethics.
Meet a Lecturer
>> Jessica Nihlén Fahlquist
Jessica Nihlén Fahlquist talks about teaching and what she thinks about responsible risk communication.
Meet a lecturer
>> Anna T. Höglund
Find out what Anna T. Höglund has to say about war, gender and the ethics of care.